Portola Pharmaceuticals to Present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/12/13 -- Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) today announced that William Lis, chief executive officer, will present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference on Tuesday, June 18, 2013, at 3:30 p.m. Eastern Time in Boston. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Portola is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis (blood clots), other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. Portola's current development-stage portfolio consists of three compounds discovered through its internal research efforts and one discovered by Portola scientists during their time at a prior company. Portola's two lead programs address significant unmet medical needs in the area of thrombosis. Portola's lead compound, betrixaban, is an investigational, novel, oral, once-daily inhibitor of Factor Xa in Phase 3 development for extended duration prophylaxis (preventive treatment) of a form of thrombosis known as venous thromboembolism (VTE) in acute medically ill patients. Currently, there is no anticoagulant approved for extended duration VTE prophylaxis in this population. Portola's second lead development candidate, PRT4445, which has a tentatively approved International Nonproprietary Name (INN) of andexanet alfa, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Portola has entered into collaboration agreements with Bristol-Myers Squibb Company and Pfizer Inc. and with Bayer Pharma AG and Janssen Pharmaceuticals, Inc. to study andexanet alfa with Eliquis(R) (apixaban) and XARELTO(R) (rivaroxaban), respectively, in Portola's Phase 2 studies. Portola retains full, worldwide commercial rights with respect to andexanet alfa. Portola's third product candida te, PRT2070, is an orally available kinase inhibitor being developed for hematologic (blood) cancers and inflammatory disorders. PRT2070 inhibits spleen tyrosine kinase (Syk) and janus kinases (JAK), enzymes that regulate important signaling pathways. Subject to regulatory approval, Portola plans to initiate a Phase 1/2 clinical study of PRT2070 in 2013 in patients with B-cell hematologic cancers who have failed or relapsed on existing marketed therapies or products in development, including patients with identified mutations. Portola's fourth program, PRT2607 and other highly selective Syk inhibitors, is partnered with Biogen Idec Inc. Contacts: Mardi Dier CFO Portola Pharmaceuticals firstname.lastname@example.org Paul Laland BrewLife email@example.com 415 946 1071
Portola Pharmaceuticals to Present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.